ZNO

0.065

66.7%

DUB

0.021

-44.7%

RLL

0.003

50%

CHM

0.005

-37.5%

DTR

0.052

40.5%

OFX

0.86

-34.6%

MM1

0.22

40.1%

DTZ

0.062

-28.7%

ALY

0.007

40%

CDEDC

0.005

-28.6%

ANR

0.007

40%

RDN

0.005

-28.6%

LTP

0.39

39.3%

EPX

0.021

-25%

CTO

0.004

33.3%

GTR

0.003

-25%

OVT

0.004

33.3%

DAL

0.023

-23.3%

ADO

0.009

28.6%

AUG

0.027

-20.6%

ATV

0.009

28.6%

ICG

0.004

-20%

LM1

0.165

26.9%

PHO

0.065

-18.8%

AVE

0.005

25%

PEK

0.275

-17.9%

KSN

0.115

25%

GBE

0.024

-17.2%

PPY

0.015

25%

FBR

0.005

-16.7%

RGL

0.005

25%

ARV

0.006

-14.3%

8CO

0.021

23.5%

AZL

0.006

-14.3%

JCS

0.033

22.2%

BLU

0.006

-14.3%

MRR

0.011

22.2%

ENL

0.03

-14.3%

MPK

0.6

21.2%

GLL

0.006

-14.3%

BlinkLab (ASX:BB1): Partners with US based

Published on Friday May 3 2024

YouTube Video VVVFRVZOQ01GU1J4RmEwQmIyd0tMUzBnLjBodGpKVHFzZnNj

BlinkLab (ASX:BB1) has initiated a clinical study in partnership with US based Turning Pointe Autism Foundation.

The data obtained during the course of this collaboration will be used to finalise the data collection and processing algorithms as well as AI/ML models ahead of the FDA registrational study expected to start in the second half of 2024.

BlinkLab is an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for autism.

Read the ASX announcement: https://yourir.info/resources/3449d9aa01a61c6b/announcements/bb1.asx/6A1205872/BB1_BlinkLab_Partnership_with_Turning_Pointe_Autism_Foundation.pdf #BB1